De Soyza Joshua, Ellis Paul, Newnham Michael, Rickard Lloyd, Turner Alice M
University of Birmingham, Institute of Applied Health Research, Birmingham, United Kingdom.
University Hospitals Birmingham, Edgbaston, United Kingdom.
Chronic Obstr Pulm Dis. 2024 Sep 27;11(5):507-514. doi: 10.15326/jcopdf.2024.0526.
Bronchiectasis occurs in patients with alpha-1 antitrypsin deficiency (AATD), but it is unknown whether an association exists independently of chronic obstructive pulmonary disease (COPD). We assessed whether bronchiectasis was associated with COPD in our cohort, and whether it has clinical significance for lung function decline, exacerbation rate, or symptoms.
PiZZ, PiSZ, and PiMZ patients from the Birmingham AATD Research Database were studied. Demographics were recorded, along with the outcomes of symptoms, forced expiratory volume in 1 second (FEV), transfer factor of carbon monoxide (TLCO), carbon monoxide transfer coefficient (KCO), and annualized exacerbation rate. Lung function decline was calculated for those with ≥3 measurements. Multivariate regression analyses were conducted to assess for associations of bronchiectasis with each outcome. A further binomial logistic regression model assessed for predictors of bronchiectasis diagnosis, including COPD. Those with alternative bronchiectasis causes were excluded from statistical models.
A total of 1290 patients were eligible. PiZZ patients with bronchiectasis were older at presentation (54 versus 49 years, <0.001), less likely to have smoked (65% versus 76.1%, =0.001), and had higher modified Medical Research Council scores (mMRC) (mMRC 2 versus 0 odds ratio [OR] 1.97, 95% constant interval [CI] 1.20-3.25, =0.008; mMRC 3 versus 0 OR 2.58 95% CI 1.59-4.19, <0.001; mMRC 4 versus 0 OR 2.2 95% CI 1.23-3.92; =0.008) than those without. The OR of bronchiectasis diagnosis was not associated with COPD diagnosis in any phenotype. Bronchiectasis was associated with lower serum alpha-1 antitrypsin levels in PiZZ patients (=0.012). Bronchiectasis was not associated with a difference in FEV percentage predicted (pp)/year decline, KCO pp/year, TLCO pp/year decline, or exacerbation rate in multivariate analysis.
Bronchiectasis exists in a significant minority of AATD patients independently of COPD and is associated with more severe shortness of breath. Appropriate treatment of bronchiectasis in AATD is essential.
支气管扩张症发生于α-1抗胰蛋白酶缺乏症(AATD)患者中,但尚不清楚其是否独立于慢性阻塞性肺疾病(COPD)存在关联。我们评估了在我们的队列中支气管扩张症是否与COPD相关,以及它对肺功能下降、急性加重率或症状是否具有临床意义。
对来自伯明翰AATD研究数据库的PiZZ、PiSZ和PiMZ患者进行了研究。记录了人口统计学数据以及症状、第1秒用力呼气容积(FEV)、一氧化碳弥散量(TLCO)、一氧化碳弥散系数(KCO)和年化急性加重率等结果。对有≥3次测量值的患者计算肺功能下降情况。进行多变量回归分析以评估支气管扩张症与每个结果之间的关联。进一步的二项逻辑回归模型评估支气管扩张症诊断的预测因素,包括COPD。有其他支气管扩张症病因的患者被排除在统计模型之外。
共有1290名患者符合条件。患有支气管扩张症的PiZZ患者就诊时年龄更大(54岁对49岁,<0.001),吸烟可能性更低(65%对76.1%,=0.001),且改良医学研究委员会评分(mMRC)更高(mMRC 2对0,优势比[OR]1.97,95%可信区间[CI]1.20 - 3.25,=0.008;mMRC 3对0,OR 2.58,95%CI 1.59 - 4.19,<0.001;mMRC 4对0,OR 2.2,95%CI 1.23 - 3.92,=0.008)。在任何表型中,支气管扩张症诊断的OR与COPD诊断均无关联。支气管扩张症与PiZZ患者较低的血清α-1抗胰蛋白酶水平相关(=0.012)。在多变量分析中,支气管扩张症与预测的FEV百分比(pp)/年下降、KCO pp/年、TLCO pp/年下降或急性加重率的差异无关。
相当一部分AATD患者存在独立于COPD的支气管扩张症,且与更严重的呼吸急促相关。对AATD患者的支气管扩张症进行适当治疗至关重要。